Meili Capital is an independent equity research practice dedicated entirely to the healthcare and life sciences sector. The premise is simple: depth beats breadth. By covering one sector closely, the research can engage with the things that actually move these companies — clinical trial data, regulatory pathways, reimbursement, and competitive pipelines.

Every note begins with the fundamentals: the underlying business, the science behind it, the addressable market, and the financials that tie it together.

The aim is to cut through the noise around a sector that is famously complex and headline-driven, and to write the kind of clear, reasoned analysis that helps readers form their own view.

This is a publication, not an advisory service. Everything here is research and commentary — a way of thinking out loud about an industry worth understanding deeply.